Gemin X to Present at the 7^th Annual BIO Investor Forum

MALVERN, Pa. & MONTREAL--(BUSINESS WIRE)--Gemin X, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced that Glenn Gormley, M.D., Ph.D., president and chief executive officer of Gemin X, is scheduled to present at The 7^th Annual BIO Investor Forum, being held October 29-31, 2008 at the Palace Hotel in San Francisco. Dr. Gormley’s presentation will take place on Wednesday, October 29, 2008 at 4:15 p.m. PDT.

About Gemin X Pharmaceuticals

Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X is developing first-in-class cancer therapeutics based on reinitiating the natural process of programmed cell death, or apoptosis, and the inhibition of metabolism in cancerous cells. Gemin X currently has three clinical development programs underway, ranging from Phase 2 clinical trials for its lead product candidates obatoclax (GX15-070), an innovative pan Bcl-2 inhibitor, and GMX1777, a novel inhibitor of NAD+ synthesis, to preclinical studies for its Telomere Capping program. Potential treatment indications for the full scope of pipeline programs span a broad range of hematological and solid tumors, including elderly acute myeloid leukemia (AML), mantle cell lymphoma (MCL), melanoma, glioblastoma, small cell lung cancer (SCLC), refractory acute lymphoblastic leukemia (ALL) and mastocytosis. Founded in 1998, Gemin X is privately held with drug development and executive headquarters in Malvern, Pennsylvania and drug discovery operations in Montréal, Canada. For more information, please visit www.geminx.com.